Antibiotic Resistance of Helicobacter pylori in Mazandaran, North of Iran

Helicobacter

Volumn 15, Issue 6, 2010, Pages 505-509

  Talebi Bezmin Abadi, Amin ^a   Mobarez, Ashraf M ^a   Taghvaei, Tarang ^b   Wolfram, Lutz ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b Faculty of Medical Science   (Iran)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antibiotic resistance; Clarithromycin; Helicobacter pylori; Iran; Metronidazole

Indexed keywords

AMOXICILLIN; CATALASE; CLARITHROMYCIN; METRONIDAZOLE; OXIDOREDUCTASE; TETRACYCLINE; UREASE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; DUODENUM ULCER; ENZYME ACTIVITY; FEMALE; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PREVALENCE; PRIORITY JOURNAL; STOMACH BIOPSY; STOMACH CANCER; STOMACH ULCER;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; CLARITHROMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IRAN; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TETRACYCLINE; YOUNG ADULT;

HELICOBACTER PYLORI;

EID: 78349279921     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2010.00795.x     Document Type: Article

References (44)

1. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, Philips M, Walter TE, Sanderson CR. Prospective double-blind of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437-42.
2. Uemura N, Okamoto S, Yamoto S, Mastumura N, Yamakido M, Taniyama K, Sasiki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
3. Marjorie MW, Teare L, McNulty C. Gastric cancer and Helicobacter pylori: the bug, the host or the environment? Postgrad Med J 2008;84:169-70.
4. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
5. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: a randomized, controlled study. Ann Intern Med 1992;116:705-8.
6. Kenneth EL. McColl Helicobacter pylori Infection. N Engl J Med 2010;362:1597-604.
7. Asaka M, Kato M, Takahashi SI, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K. Guidelines for the Management of Helicobacter pylori Infection in Japan: 2009 Revised Edition. Helicobacter 2010;10:1-20.
8. Ruggiero F, Lionetti E, Castellaneta S, Margiotta M, Piscitelli D, Lorenzo L, Cavallo L, Ierardi E. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. J Pediatr 2010;157:228-32.
9. Mishra KK, Srivastava S, Garg A, Ayyagari A. Antibiotic susceptibility of Helicobacter pylori clinical isolates: comparative evaluation of disk-diffusion and E-test methods. Curr Microbiol 2006;53:329-34.
10. Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003;17:99-109.
11. Babamahmoodi B, Ajami A, Kalhor M, Shafiei GR, Kalilian A. A Sero epidemiological study of Helicobacter pylori infection in Sari. JMMS 2004;12:39-48.
12. Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med 2009;12:576-83.
13. Kim JM, Kim JS, Jung HC, Song IS, Kim CY. Virulence factors of Helicobacter pylori in Korean isolates do not influence proinflammatory cytokine gene expression and apoptosis in human gastric epithelial cells, nor do these factors influence the clinical outcome. J Gastroenterol 2000;35:898-906.
14. Boyanova L, Mentis A, Gubina M, Rozynek E, et al. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect 2002;8:388-96.
15. National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, 4th edn. Approved Standard M11-A4. Wayne, Pa: NCCLS, 1997.
16. Agar Dilution Susceptibility Test Procedure Approved at the Subcommittee Level. Tampa, Florida: January 13, 1998.
17. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998;115:1278-82.
18. Novesti B, Nicolin FT, Ndipt RN. Increasing trend of metronidazole resistance in the treatment of Helicobacter pylori infection: a global challenge. Afr J Biotechnol 2010;9:1115-21.
19. Mohammed AMM. Patterns of H. pylori resistance to metronidazole, clarithormycin and amoxicillin in Saudi Arabia. J Bacteriol Virol 2008;38:173-8.
20. Van der Wouden EJ, Van Zwet AA, et al. Rapid increase in the prevalence of metronidazole- resistant Helicobacter pylori in the Netherlands. Emerg Infect Dis 1997;3:385-9.
21. Mohammadi M, Doroud D, Mohajerani N, Massarrat S. Helicobacter pylori antibiotic resistance in Iran. World J Gastroenterol 2005;7:6009-13.
22. Eltahawy AT. Prevalence of primary Helicobacter pylori resistance to several antimicrobials in Saudi teaching hospital. Med Princ Pract 2002;11:65-8.
23. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CM. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and Trovafloxacin in the Netherlands. J Antimicrob Chemother 1999;43:511-5.
24. Boyanova L, Stancheva I, Spassova Z, Katzarov N, Mitov I, Koumanova R. Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria. J Med Microbiol 2000;49:415-8.
25. Bago J, Majstorovic K, Belosic-Halle Z, Kucisec N, Bakula V, Tomic M, Bago P, Troskot R. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in Helicobacter pylori eradication-a randomised controlled trial. Wien Klin Wochenschr 2002;114:448-53.
26. Njume C, Afolayan AJ, Ndip RN. An overview of antimicrobial resistance and the future of medicinal plants in the treatment of Helicobacter pylori infections. Afr J Pharm Pharmacol 2009;3:685-99.
27. Vécsei A, Kipet A, Innerhofer A, et al. Time trends of Helicobacter pylori resistance to antibiotics in children living in Vienna, Austria. Helicobacter 2010;15:214-20.
28. Toracchio S, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 2003;35:541-5.
29. Parsons HK, Carter MJ, Sanders DS, Winstanley T, Lobo AJ. Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther 2001;15:1473-8.
30. Raymond J, Lamarque D, Kalach N, Chaussade S, Burucoa C. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 2010;15:21-7.
31. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicentre, North American trial. Am J Gastroenterol 2003;98:562-7.
32. Alizadeh RS, Siavoshi F, Malekzadeh R. Furazolidone antimicrobial effectiveness against metronidazole resistant strains of Helicobacter pylori. East Mediterr Health J 2006;12:286-93.
33. Siavoshi F, Safari F, Doratotaj D, Khatami GR, Fallahi GH, Mirnaseri MM. Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children. Arch Iran Med 2006;9:308-14.
34. Ndip RN, Takang AEM, Ojongokpoko JEA, Luma HN, Malongue A, Akoachere JFTK, Ndip LM, Martin MacMillan M, Weaver LT. Helicobacter pylori isolates recovered from gastric biopsies of patients with gastro-duodenal pathologies in Cameroon: current status of antibiogram. Trop Med Int Health 2008;13:848-54.
35. AlMalki AS. Helicobacter pylori eradication in nonulcer dyspepsia: does it really matter? Saudi J Gastroenterol 2008;14:93-5.
36. Mukhopadhyay AK, Kersulyte D, Jeong JY, Datta S, Ito Y, Chowdhury A, Chowdhury SA, et al. Distinctiveness of genotypes of Helicobacter pylori in Calcutta, India. J Bacteriol 2000;182:3219-27.
37. Adeyemi EO, Fadlalla H, Al-Homsi M. Clinicopathological assessment of gastric biopsy samples of patients with helicobacter pylori infection metronidazole resistance and compliance problems in the United Arab Emirates. Ital J Gastroenterol 1992;24:436-9.
38. Yilmaz O, Demiray E. Clinical role and importance of fluorescence in situ hybridization method in diagnosis of Helicobacter pylori infection and determination of clarithromycin resistance in H. pylori eradication therapy. World J Gastroenterol 2007;13:671-5.
39. Rafeey M, Ghotaslou R, Nikvash S, Ashrafy-Hafez A. Primary resistance in Helicobacter pylori isolated in children from Iran. J Infect Chemother 2007;13:291-5.
40. Khashei R, Shojaei H, Adibi P, Shavakhi A, Aslani MM, Naser AD. Genetic diversity and drug resistance of Helicobacter pylori strains in Isfahan, Iran. Iranian J Basic Med Sci 2008;11:174-82.
41. Saberi-Firoozi M, Nejabat M. Experiences with Helicobacter pylori treatment in Iran. Iranian J Med Sci 2006;31:181-5.
42. Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh BZ, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high misonidazole resistance rate. Aliment Pharmacol Ther 2001;15:411-6.
43. Wu H, Shi XD, Wang HT, Liu JX. Resistance of Helicobacter pylori to metronidazole, tetracycline, and amoxicillin. J Antimicrob Chemother 2000;46:121-3.
44. Piccolomini R, Di Bonaventura G, Catamo G. Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents. J Clin Microbiol 1997;35:1842-6.